Literature DB >> 19278301

Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers.

M Wasif Saif1, Ewan Tytler, Frederick Lansigan, David M Brown, Alan J Husband.   

Abstract

Flavonoids, in particular the isoflavones, are naturally occurring compounds found in soy and textured vegetables that have antiproliferative effects on a variety of cancer types. Phenoxodiol is a derivative of the isoflavone genisten that is 5-20 times more potent than genisten. Triphendiol is a derivative of phenoxodiol that has superior anticancer activity against pancreatic and bile duct cancers. This review will focus on the mechanisms of action and activity of two isoflavone derivatives, phenoxodiol and triphendiol, in various tumor types, especially pancreaticobiliary cancers. Triphendiol induces apoptosis in pancreatic cell lines by both caspase-mediated and caspase-independent mechanisms. The addition of triphendiol to gemcitabine is synergistic in in vitro and in vivo models of pancreatic cancer and represents a novel combination of drugs for pancreatic cancer patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19278301     DOI: 10.1517/13543780902762835

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  6 in total

Review 1.  Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.

Authors:  Zhiyan Xiao; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-09-11       Impact factor: 12.944

Review 2.  Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer.

Authors:  Koh Miura; Wataru Fujibuchi; Kazuyuki Ishida; Takeshi Naitoh; Hitoshi Ogawa; Toshinori Ando; Nobuki Yazaki; Kazuhiro Watanabe; Sho Haneda; Chikashi Shibata; Iwao Sasaki
Journal:  Surg Today       Date:  2011-01-26       Impact factor: 2.549

Review 3.  The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome.

Authors:  Yiwei Li; Vay Liang W Go; Fazlul H Sarkar
Journal:  Pancreas       Date:  2015-01       Impact factor: 3.327

4.  Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling.

Authors:  Chunyan Sun; Meixia Zhang; Xiaolei Shan; Xueying Zhou; Jiao Yang; Yanli Wang; Jesse Li-Ling; Yihui Deng
Journal:  J Cancer Res Clin Oncol       Date:  2009-10-09       Impact factor: 4.553

5.  A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models.

Authors:  Ahcene Boumendjel; Anne McLeer-Florin; Pierre Champelovier; Diane Allegro; Dima Muhammad; Florence Souard; Madiha Derouazi; Vincent Peyrot; Bertrand Toussaint; Jean Boutonnat
Journal:  BMC Cancer       Date:  2009-07-20       Impact factor: 4.430

6.  NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study.

Authors:  Koba Kiknavelidze; Mikheil Shavdia; Nana Chikhladze; Lia Abshilava; Marinella Messina; Gisela Mautner; Graham Kelly
Journal:  Curr Ther Res Clin Exp       Date:  2021-03-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.